Search

Infant, maternal and demographic predictors of delayed vaccination: A population-based cohort study

Receiving vaccines at or close to their due date (vaccination timeliness) is a now key measure of program performance. However, studies comprehensively examining predictors of delayed infant vaccination are lacking. We aimed to identify predictors of short and longer-term delays in diphtheria-tetanus-pertussis (DTP) vaccination by dose number and ethnicity.

Cohort profile: A population-based record linkage platform to address critical epidemiological evidence gaps in respiratory syncytial virus and other respiratory infections

The Western Australia (WA) Respiratory Infections Linked Data Platform is a population-based cohort established to investigate the epidemiology of RSV and other respiratory infections in children aged 0-10 years, incorporating microbiological testing patterns, hospital admissions, emergency department presentations, and socio-demographic data.

Nirsevimab immunisation of infants and respiratory syncytial virus (RSV)-associated hospitalisations, Western Australia, 2024: a population-based analysis

Christopher Peter Hannah Blyth Richmond Moore MBBS (Hons) DCH FRACP FRCPA PhD MBBS MRCP(UK) FRACP OAM BSc (Hons) GradDipClinEpi PhD Centre Head,

Estimating the impact of Western Australia's first respiratory syncytial virus immunisation program for all infants: A mathematical modelling study

The Australian Therapeutic Goods Administration approved the use of nirsevimab, a long-acting monoclonal antibody for the prevention of Respiratory Syncytial Virus (RSV), in November 2023. Western Australia (WA) implemented a combination of nirsevimab administration strategies designed to protect all infants starting in April 2024, before the epidemic season. We developed a dynamic transmission model to predict the impact of WA's RSV immunisation program on infant hospitalisations.

AusVaxSafety

Christopher Peter Peter Tom Blyth Jacoby Richmond Snelling MBBS (Hons) DCH FRACP FRCPA PhD BA (Hons) MSc MBBS MRCP(UK) FRACP BMBS DTMH GDipClinEpid

Protective Vaccine Responses in Infants after Maternal Pertussis Vaccination (PRIME) Study

Christopher Jennifer Peter Blyth Kent Richmond MBBS (Hons) DCH FRACP FRCPA PhD RN MBBS MRCP(UK) FRACP Centre Head, Wesfarmers Centre of Vaccines and

Epidemiology and mortality of staphylococcus aureus Bacteremia in Australian and New Zealand children

Describe the epidemiology of Staphylococcus aureus bacteremia in children and adolescents younger than 18 years from Australia and New Zealand

Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines

Systematic review of antibiotic duration and timing of intravenous to oral switch for paediatric infectious diseases and evidence-graded recommendations

Invasive Meningococcal Disease in Australian Children 2016–2022: A Prospective Surveillance Study of Serogroup Distribution and Clinical Presentation in the Meningococcal Vaccine Era

Although uncommon, invasive meningococcal disease (IMD) results in death in 5%-10% of cases in healthy children and adolescents. This study aimed to examine demographics, clinical presentation, treatment and outcomes of Australian children hospitalized with IMD during the introduction of the meningococcal vaccine program, overall and by serogroup/disease severity. 

Association between village coverage of 13-valent pneumococcal conjugate vaccine and vaccine-type pneumococcal carriage among children aged 0–59 months with pneumonia in Papua New Guinea

Pneumococcal conjugate vaccine (PCV) prevents pneumococcal disease and pneumonia, but indirect effects are poorly understood in low-coverage, high-burden settings like Papua New Guinea (PNG). PNG introduced 13-valent PCV (PCV13) in 2014. We aimed to assess direct and indirect effectiveness of PCV13 against vaccine-type pneumococcal carriage among children with pneumonia or suspected meningitis in PNG